Heterogeneity of microbiome responses to menopausal hormone therapy among perimenopausal women.

Menopausal hormone therapy (MHT) alleviates climacteric symptoms, yet its microbiome-wide effects and efficacy determinants remain unclear. Here we show that oral estradiol/dydrogesterone, given for 6 months to 356 perimenopausal women, improved neuroendocrine, metabolic and symptom outcomes and induced site-specific microbial remodeling. Vaginocervical and urinary niches showed the most pronounced restructuring, with moderate oral and minimal gut changes. MHT increased vaginocervical Lactobacil
Menopausal hormone therapy (MHT) alleviates climacteric symptoms, yet its microbiome-wide effects and efficacy determinants remain unclear. Here we show that oral estradiol/dydrogesterone, given for 6 months to 356 perimenopausal women, improved neuroendocrine, metabolic and symptom outcomes and induced site-specific microbial remodeling. Vaginocervical and urinary niches showed the most pronounced restructuring, with moderate oral and minimal gut changes. MHT increased vaginocervical Lactobacillus crispatus and reduced Gardnerella vaginalis. Higher baseline vaginocervical L. crispatus predicted greater postintervention vaginocervical and urinary colonization and superior Female Sexual Function Index improvement. Baseline vaginocervical community types determined differential outcomes: G. vaginalis-dominated individuals shifted most toward healthier communities, whereas diversified individuals improved least. MHT efficacy also varied according to baseline gut community type: Phocaeicola vulgatus-dominated women exhibited greater hormonal responsiveness, superior clinical outcomes and were more likely to achieve 4-week rapid clinical remission than Prevotella copri-dominated women. These findings support a precision MHT framework integrating gut and vaginocervical community typing for personalized care. Chictr.org.cn ID: ChiCTR2100049768 .




